Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2026-526485-25-00
Authorised, not yet recruiting Phase II

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis

2026-526485-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
Triveni Bio Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Skin and Connective Tissue Diseases
Decision date
20/10/2026
Enrollment target
43
Sites
Czechia, Poland

Condition studied

Atopic dermatitis

Investigational medicinal product(s)

TRIV-573-PlaceboTRIV-573

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Percentage of participants with improvement of AD

Endpoint detail

1. Percentage of participants with improvement of AD, 5. Percentage of participants with TEAEs, 6. Percentage of participants with SAEs, 7. Changes in vitals signs, ECG parameters, physical examination, and safety laboratory values, 8. Single and multiple-dose PK parameters, 9. Percentage of participants with anti-TRIV-antibodies

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526485-25-00 on CTIS ↗ ← All trials in the EU